0001209191-21-066261.txt : 20211122
0001209191-21-066261.hdr.sgml : 20211122
20211122202331
ACCESSION NUMBER: 0001209191-21-066261
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211118
FILED AS OF DATE: 20211122
DATE AS OF CHANGE: 20211122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Larson Tina Marriott
CENTRAL INDEX KEY: 0001856414
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40323
FILM NUMBER: 211434372
MAIL ADDRESS:
STREET 1: C/O RECURSION PHARMACEUTICALS
STREET 2: 41 S. RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-18
0
0001601830
RECURSION PHARMACEUTICALS, INC.
RXRX
0001856414
Larson Tina Marriott
41 S. RIO GRANDE STREET
SALT LAKE CITY
UT
84101
0
1
0
0
President and COO
Class A Common Stock
2021-11-18
4
S
0
1798
18.8145
D
50702
D
Class A Common Stock
2021-11-18
4
S
0
702
19.2015
D
50000
D
Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.10 to $19.06 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $19.13 to $19.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
/s/ Nathan Hatfield, attorney-in-fact
2021-11-22